Professor Per Kogner and his research team at Karolinska Institute in Sweden have found that omega-3 fatty acids inhibit cancer growth.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 365 entries.
Entries by oslocancer
Oslo’s cancer research community attracts international attention. Foreign companies engaged in the cancer field are flocking to Norway and Oslo to benefit from the city’s cancer research community.
Can the Healthcare Industry become a significant future growth platform? DNB invites all key personell on healthcare industry to an informal gatering.
Last year, a new vaccine technology aiming to manipulate our immune system and thereby combat cancer and HIV won Inven2’s idea competition. Do you have an idea that you want to further develop?
Yesterday Minister of Education Røe Isaksen and the Minister of Health Bent Høie visited Lytix Biopharma at the Department of Cell therapy at the Cancer Research Institute/Oslo University Hospital.
Oslo Cancer Cluster member BerGenBio AS has been granted a 1.6 million (NOK 16 million) Seeding Drug Discovery Award from the UK’s Wellcome Trust.
Oslo Cancer Cluster member Lytix Biopharma is one of three biotech companies awarded Nordic Stars 2014.
A very strong Scandinavian immunotherapy delegation is in the US September 15-19 to meet peers from some of the most prominent institutions “over there”.
Janssen wish to strengthen their medical affairs team in Norway and hereby we are seeking 2 field based Medical advisors to support our business in CNS and Oncology.
Karl Simpson from Liftstream, a company that provides recruitment services to the global life sciences sector, visited the Oslo Cancer Cluster this Summer.
Norwegian Healthcare actors have joined forces and launch the “Norwegian package” at next weeks Nordic Life Science Days/ECCP.
Oslo Cancer Cluster Incubator AS is looking for a General Manager. Oslo Cancer Cluster Incubator is a private company, 100% owned by Oslo Cancer Cluster SA.
Professor Ragnhild A. Lothe, Head of Dept of Cancer Prevention at Oslo University Hospital, will lead the new K.G.Jebsen Colorectal Cancer Research Centre that officially opened late August.
The Board of Nordic Nanovector is pleased to announce the appointment of Mr. Luigi Costa as new CEO.
PCI Biotech reports that the treatment evaluation of the second group in the ENHANCE study has been completed.
At least 17 Oslo cancer Cluster members will be represented in Stockholm September 7-9.
Oslo Cancer Cluster, in collaboration with Radiumhospitalets Legater, invite members and collaborators to the annual Oslo Cancer Cluster R&D Summer Meeting on Wednesday August 20th at the Auditorium , Institute of Cancer Research. Download program and register here The summer meeting will kick off the Oslo Cancer Cluster Innovation Park, and for the first time it […]
More than 170 people kicked-off the Oslo Cancer Cluster Innovation Park, opening in less than a year.
Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed.
In April 2014, Pharma TV interviewed Ketil Widerberg, General Manager of Oslo Cancer Cluster. Watch the interview and learn more about how Oslo Cancer Cluster works to develop new diagnostics and medication.
The HelseOmsorg21 strategy process was launched in 2013 by the Ministry of Health and Care services.
The program for the ECCP Oncology Track Sessions at NLS Days/ECCP in Stockolm is now ready. We are proud to present a strong program with international renowned speakers, representing the entire oncology value chain.
Researchers, clinicians and start-ups filled up the seminar room when Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 invited to a breakfast meeting on June 18th. The breakfast seminar had a special focus on protecting oncology innovations.
The Norwegian Research Council will grant NOK 850 million to industry innovation projects – the largest grant of its kind in history. Application deadline is October 15, 2014.
Oslo Cancer Cluster member Nordic Nanovector announce that the company has closed its pre-IPO private placement of NOK 250 million – 100 million more than anticipated.
Are you aiming for Asian markets? Innovation Norway presents the Tech Incubator Program – TINC TINC in Silicon Valley has created great opportunities for Norwegian tech entrepreneurs and has been fundamental in Innovation Norway’s efforts towards global entrepreneurs. These days the concept is extended to Asian markets with Singapore as the epicenter. Innovation Norway’s competence […]
Targovax AS is registered on the NOTC-list from June 16th, 2014, with ticker code TRVX. The company has issued 9 429 404 shares, each at par value NOK 0.10. All shares are registered in VPS with ISIN code NO 001 0689326. Based on the most recent capital increase, June 4th, 2014, where the shares were […]
Oslo Cancer Cluster member Nordic Nanovector`s lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]
MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]
Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]
The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro and […]
Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial. Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster […]
Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 kindly invite researchers, clinicians and start-ups to learn more about securing IPR in oncology projects.
Smartfish is a Norwegian company developing synergistic omega 3 based pharmaconutrition products. Smartfih is now studying the effect of their phamaconutrition on the immune system, and would like to get in contact with Norwegian collaborators. Smartfish joined the Oslo Cancer Cluster in 2014 and currently have two products on the market that have been clinically […]
The Norwegian Cancer Society (NCS) have established an investment fund for Norwegian oncology companies, and their first investment are in Oslo Cancer Cluster Member Vaccibody.
Present your oncology innovation to the global life science industry at the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering (ECCP).
The PCI Biotech stock went straight up on the Norwegian Stock Exchange after successful results from the first dose cohort in the phase I/II study in patients with bile duct cancer. No safety concerns were observed at this dose level.
The liberal party Venstre have proposed the implementation of the “Helsemyggordningen,” a financial mechanism for stimulation of health innovation, for the Norwegian Parliament. The proposal have been designated to the The Standing Committee on Finance and Economic Affairs in the Parliament.
The Radium Hospital Foundation (Radiumhospitalets Legater) will support the Oslo Cancer Clusters R&D Network Meetings 2014, and collaborate closely with the cluster on developing these meetings.
The Fridtjof Nansen prize for excellent research in science and medicine 2014 is awarded to Centre for Cancer Biomedicine’s Kirsten Sandvig for her groundbreaking work within biochemistry and cell biology.
Cancer Crosslinks 2014, January 23, was the 6th edition of this annual oncology conference bringing together hematologists, oncologists and the industry in Norway.
BerGenBio AS, an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013.
Immunotherapy specialist Targovax reaches Phase IIa in operable pancreatic cancer with its TG01 immunotherapy. RAS specific immune responses were induced in all 6 patients in Phase I, and no substantial side effects were observed in the patients. The clinical trial has now expanded from Norway to two sites in the UK
May 2015 is THE grand opening of Oslo Cancer Cluster Innovation Park and Oslo Cancer Cluster Incubator. Would you like to join us in the fight against cancer by being part of a power centre for developing innovative cancer treatment? Contact us now, and see what we may offer you as a tenant in the Innovation Park or the Incubator.
Oslo Cancer Cluster and French partner Cancer-Bio-Santé are joining forces with SwedenBio to offer the global Life Science industry the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering. Already now oncology biotechs, early stage companies and academics may submit an application for presenting at NLSDays-ECCP […]
The Norwegian Research Council recently granted BerGenBio, PCI Biotech, Lytix Biopharma, Oncoinvent and Ultimovacs – all Oslo Cancer Cluster member companies – funding through the Programme for User-Driven Research Based Innovation (BIA).
Friday January 31 Oslo Cancer Cluster, SINTEF, NTNU, Oslo University Hospital and the Norwegian Cancer Society invite Norwegian media and other interested parties to join a breakfast seminar on nano cancer medicine. The seminar is held in conjunction with 12 similair events across the whole of Europe in relation to Nano World Cancer Day. Below […]
Six biology students from Ullern High School were selected to intern at the Department of Tumor Biology at Oslo University Hospital in week 50. This is the fourth time the department has had students from Ullern interning, says researcher Birgit Engesæter. Together with her research colleague Siri Tveito, she is in charge of the students […]
The newly employed Head of Biotech Investments in The Norwegian Cancer Society, Sigrid Fossheim, has already had several meetings with potential oncology companies to invest in. – We aim to make our first investment before the Summer of 2014, says Fossheim.
The six year evaluation of Oslo Cancer Cluster as a Norwegian Centre of Expertise concludes that Oslo Cancer Cluster is a strong biotech cluster, well positioned within the global oncology industry. “This plays well with our ambition to take the step up a level and become a Global Centre of Excellence,” says Jónas Einarsson, acting CEO […]
Despite keen competition from other outstanding medical research groups, Oslo Cancer Cluster Board members Professor Ragnhild A. Lothe and Professor Rolf Bjerkvig have won the competition for funds for new K.G. Jebsen centres in the field of medicine – a long side John-Bjarne Hansen.
Oslo Cancer Cluster member BerGenBio announce that preclinical studies on the agent BGB324 may be effective as new treatment for patients with drug resistant Chronic Myeloid Leukemia (CML). The data was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH) early December.
December 11th 2013, Oslo Cancer Cluster, Oslo Medtech and Nansen Neuroscience Network launched a proposal for a new financing mechanism to stimulate innovation from the health- and biotech industry.
Oslo Cancer Cluster member Bayer HealthCare announced Monday December 9th that they just received the marketing approval for Xofigo® (radium Ra 223 dichloride) by the Norwegian Medicines Agency. The approval came approximately one month after the European Commission granted marketing authorization in the EU for Xofigo® on November 15 2013.
Oslo Cancer Cluster member Lytix Biopharma AS has completed a successful issue that was subscribed shares of over 50 million NOK.
Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks.
Inven2 grants exclusive worldwide license to its epidermal growth factor receptor (EGFR) inhibitors patent portfolio to Merck. Researchers and clinicians at Sørlandet Hospital have discovered that the EGFR inhibitors may play a vital role as a pain reliever for so called neuropathic pain.
Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo® for the treatment of prostate cancer patients with bone metastases.
Three Oslo Cancer Cluster SME`s emerged as the winners of the Immuno-Oncology Innovation Call. Oncoinvent was as a clear number one of the 10 applications received.
The 2013 year’s grant to cancer research in Norway, 160 million NOK (EUR 20 M) is the largest grant the Norwegian Cancer Society has ever given.
The new government of Norway has launched their political platform. Oslo Cancer Cluster have reviewed the political platform document. We are overall very pleased with the initiatives that concerns research, knowledge, education, business and R&D.
Oslo Cancer Cluster was the proud host of a press conference in early October, where two of the Nordic region’s largest governmental venture investors Investinor and Industrifonden announced their NOK million 90 investment in Swedish biotech Pharmalink.
Life Technologies Corporation has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Both Novartis and Life Technologies are member of Oslo Cancer Cluster.
Now in its fourth year as a member of the Oslo Cancer Cluster, Ockham Oncology unveils its stronger global oncology expertise, as a fully integrated, pure oncology-focused international partner.
Oslo Cancer Cluster, the Norwegian Cancer Society and the Association of the Pharmaceutical Industry in Norway join forces in pushing for a new cancer drugs fund. The purpose of the fund is to ensure equal and quicker access to new approved cancer drugs in Norway. A cancer drugs fund would cover the costs of […]
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.